Silver nanoparticles combined with ROS-generating drugs could potentially enhance therapeutic efficacy against acute myelomonocytic leukemia cells.
Colloidal silver nanoparticles improve anti-leukemic drug efficacy via amplification of oxidative stress.
AI Summary
Key Findings
Abstract
Recently, increased reactive oxygen species (ROS) levels and altered redox status in cancer cells have become a novel therapeutic strategy to improve cancer selectivity over normal cells. It has been known that silver nanoparticles (AgNPs) display anti-leukemic activity via ROS overproduction. Hence, we hypothesized that AgNPs could improve therapeutic efficacy of ROS-generating agents against leukemia cells. In the current study, N-(4-hydroxyphenyl)retinamide (4-HPR), a synthetic retinoid, was used as a drug model of ROS induction to investigate its synergistic effect with AgNPs. The data exhibited that AgNPs with uniform size prepared by an electrochemical method could localize in the lysosomes, mitochondria and cytoplasm of SHI-1 cells. More importantly, AgNPs together with 4-HPR could exhibit more cytotoxicity and apoptosis via overproduction of ROS in comparison with that alone. Taken together, these results reveal that AgNPs combined with ROS-generating drugs could potentially enhance therapeutic efficacy against leukemia cells, thereby providing a novel strategy for AgNPs in leukemia therapy.
Affiliation
Dawei Guo
External References
- PubMed ID:
- 25576804
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.